

**PB 77 of 2024**

**National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024
(No. 7)**

*National Health Act 1953*

I, NIKOLAI TSYGANOV, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 84AAA(2) of the *National Health Act 1953*.

Dated 30 July 2024

**NIKOLAI TSYGANOV**

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Schedules 1

Schedule 1—Amendments 2

National Health (Pharmaceutical benefits—early supply) Instrument 2015
(PB 120 of 2015). 2

1 Name

1. This instrument is the *National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024 (No. 7)*.
2. This instrument may also be cited as PB 77 of 2024.

2 Commencement

1. Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information |
| --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. *The whole of this instrument* | *1 August 2024* | *1 August 2024* |

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

1. Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 84AAA(2) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

*National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)*

1. Schedule 1, after entry for Adalimumab in the form Injection 20 mg in 0.2 mL pre-filled syringe *[Maximum quantity or number of units: 2; Maximum number of repeats: 5]*

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  | 20 | 2 | 6 |  |

1. Schedule 1, after entry for Adalimumab in the form Injection 40 mg in 0.4 mL pre-filled pen *[Maximum quantity or number of units: 2; Maximum number of repeats: 5]*

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  | 20 | 2 | 6 |  |

1. Schedule 1, after entry for Adalimumab in the form Injection 40 mg in 0.8 mL pre-filled pen *[Maximum quantity or number of units: 2; Maximum number of repeats: 5]*

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  | 20 | 2 | 6 |  |

1. Schedule 1, after entry for Adalimumab in the form Injection 40 mg in 0.8 mL pre-filled syringe *[Maximum quantity or number of units: 2; Maximum number of repeats: 5]*

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  | 20 | 2 | 6 |  |

1. Schedule 1, entry for Atorvastatin in the form Tablet 20 mg (as calcium)

*omit:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  | 20 | 30 | 11 |  |

1. Schedule 1, entry for Atorvastatin in the form Tablet 80 mg (as calcium)

*omit:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  | 20 | 30 | 11 |  |

1. Schedule 1, entry for Fenofibrate in the form Tablet 48 mg

*omit:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  | 20 | 60 | 11 |  |

1. Schedule 1, entry for Fenofibrate in the form Tablet 145 mg

*omit:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  | 20 | 30 | 11 |  |

1. Schedule 1, entry for Fluvastatin

*omit:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  | 20 | 28 | 11 |  |

1. Schedule 1, entry for Gemfibrozil

*omit:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  | 20 | 60 | 11 |  |

1. Schedule 1, omit entry for Oxprenolol
2. Schedule 1, after entry for Selegiline

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Selumetinib | Capsule 10 mg | 20 | 60 | 5 |  |
|  | Capsule 25 mg | 20 | 60 | 5 |  |

1. Schedule 1, entry for Simvastatin in each of the forms: Tablet 5 mg; Tablet 10 mg; Tablet 20 mg; Tablet 40 mg; and Tablet 80 mg

*omit:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  | 20 | 30 | 11 |  |

1. Schedule 1, entry for Sulfasalazine in each of the forms: Tablet 500 mg; and Tablet 500 mg (enteric coated)

*omit:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  | 20 | 200 | 11 |  |

1. Schedule 1, entry for Teriparatide

*omit:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Injection 250 micrograms per mL, 2.4 mL in multi-dose pre-filled cartridge | 20 | 1 | 5 |  |